Sitenali -D 50/5MG Tab

Tablet

Type 2 diabetes mellitus (as an add-on to diet and exercise) to improve glycaemic control when dual therapy is appropriate.

Sitagliptin is a DPP-4 inhibitor that increases incretin hormones, boosting insulin release and reducing glucagon in a glucose-dependent manner. Dapagliflozin is an SGLT2 inhibitor that lowers blood glucose by increasing urinary glucose excretion via the kidneys.

Oral tablet; take exactly as prescribed, usually once daily at the same time each day, with or without food. Maintain adequate hydration; follow diet/exercise plan and monitor blood glucose as advised.

Urinary tract infection, genital fungal infection, increased urination, thirst, headache, nasopharyngitis, nausea, dizziness

Not for type 1 diabetes or diabetic ketoacidosis. Risk of dehydration/low blood pressure; maintain fluids especially in elderly or with diuretics. May cause genital/urinary infections; seek care for fever, burning urination, genital itching/discharge. Rare but serious: pancreatitis (severe abdominal pain), ketoacidosis (nausea, vomiting, abdominal pain, rapid breathing), severe allergic reactions. Use caution in kidney impairment; dose/appropriateness depends on eGFR—periodic renal function monitoring needed. Stop and consult doctor before major surgery or during prolonged fasting/acute illness as advised.

Diuretics (increased dehydration/hypotension risk), insulin or sulfonylureas (increased hypoglycaemia risk), strong CYP3A4/UGT inducers such as rifampicin/phenytoin/carbamazepine (may reduce dapagliflozin effect), digoxin (monitor—sitagliptin may slightly increase levels), alcohol/excess fasting (increases ketoacidosis risk)

Store below 25°C in a cool, dry place; protect from moisture and light; keep in original blister and out of reach of children.

Janumet XR 50/500 Tablet, Istamet 50/500 Tablet, Galvus Met 50/500 Tablet, Jalra-M 50/500 Tablet, Kombiglyze XR 5/500 Tablet